

## REMARKS

Reconsideration of this application and reexamination of the pending claims in view of the amendments and remarks herein are respectfully requested. The listing of claims provided herein amends claims 23, 78, and 99. The claim amendments are fully supported by the application as filed and do not introduce new matter. Claims 23-34, and 72-100 are pending. Of these, claims 31, 72-77, 86 and 90-95 are withdrawn from consideration as drawn to a non-elected invention.

Applicants thank the Examiner for withdrawing the rejections made in the prior Office Action in view of the Amendment and Response filed April 28, 2005. In the current Office Action claims 23-30, 32-34, 78-85, 87-89 and 96-100 were rejected under 35 U.S.C. § 112, first paragraph because the Office contends the specification, while being enabling for the method of treating a *Flaviviridae* virus infection, does not reasonably provide enablement treatment wherein the inhibition of binding between the *Flaviviridae* virus and the effector molecule is greater than 80%.

In response, Applicants have amended the claims as suggested by the Examiner to remove the language referring to percent inhibition. Applicants submit that this Amendment obviates the stated basis for the rejection, and that the claims are fully enabled throughout their scope. In view of the amendment to the claims, withdrawal of the enablement rejection is appropriate and respectfully requested.

Applicants respectfully submit that, in view of the amendment made herein, claims 23-30, 32-34, 78-85, 87-89 and 96-100 are allowable. Applicants renew their request that the Office rejoin claims 31, 72-77, 86 and 90-95 to the remaining claims in the application and allow them to issue together at this time.


Reconsideration and reexamination of this application are respectfully requested. Applicants respectfully request that this amendment under 37 C.F.R. § 1.116 be entered by the Examiner, placing claims 23-34 and 72-100 in condition for allowance. Because Applicants have addressed the sole remaining basis of rejection by amendment of the claims, Applicants submit that this amendment should allow for immediate action by the Examiner.

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: October 25, 2005

By: 

Kenneth J. Meyers  
Reg. No. 25,146